Bright Green enters partnership with Benuvia Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2024
0mins
Should l Buy ?
Supply Agreement: Bright Green has signed a letter of intent to supply DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, highlighting its commitment to providing high-quality organic materials for US pharmaceutical partners.
Compliance and Production: The agreement aims for Benuvia to utilize Bright Green's capabilities to produce Schedule I & II raw materials in compliance with regulatory standards, facilitating the manufacture of cGMP pharmaceutical-grade Active Pharmaceutical Ingredients for both US and global markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
